Israeli medical cannabis firm Tikun Olam-Cannbit has signed a partnership agreement with Gynica to launch a groundbreaking clinical trial.
The French company, which is developing cannabis-based products for women’s health, will work with its new partner to launch a ‘first of its kind’ clinical study into vaginal health products.
The deal shares deal is worth around £1.1m and will see Tikun Olam-Cannabit ‘Gynica with an array of services for development of vaginal suppositories, lubricating gel and additional future products that contain cannabinoids’
Gynica will also benefit from the supply of raw cannabis materials and the establishment of a dedicate production line.
The joint clinical study will be led by Prof. Moshe Hod, a renowned international gynaecology expert and President of the European Association of Perinatal Medicine (EAPM)
Avinoam Sapir, CEO of Tikun Olam-Cannbit, said: “The acquisition agreement for Gynica is part of our strategy to become a cannabis-based pharmaceutical company.
“We differentiate ourselves by not sufficing with inflorescence and oils, but strive for precise pharmaceutical formulations, with a precise indication that have been proven clinically effective through research.
“Gynica specialises in scientific and technological medical cannabis innovation for women and is one of the first companies in the world to conduct clinical research on a cannabis-based vaginal product.
“This is a market with a very strong potential, with markets such as Canada, Australia and the UK, which have a growing demand for these products and regulation that makes it possible”
Prof. Moshe Hod, president of Gynica said: “Gynica, a global pioneer in research and development of cannabis-based products for the treatment of gynaecological issues, is excited to partner with medical cannabis pioneer, Tikun Olam-Cannbit.
“This partnership is an important milestone in improving the quality of life of hundreds of thousands of women in Israel and millions of women worldwide who to date have not received a safe and proper solution for the variety of problems and symptoms they experience daily, and there is no doubt that Tikun Olam-Cannbit’s entry into the production and marketing of advanced and clinically proven cannabis-based products marks a breakthrough for gynaecology and the industry as a whole.”
[activecampaign form=31]
